Newest Biotech Joins China mRNA COVID Vaccine Race
Other Supply Deals Reached
Additional Chinese coronavirus vaccine makers are now building up capacity, with Beijing-based AIM Vaccine preparing for a 400 million dose per year production capability for mRNA vaccines, while Chengdu-based Clover is to supply up to 414 million doses of its vaccines to GAVI.
You may also be interested in...
Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
World A Step Closer To First Human Plasmid DNA Vaccine As Zydus Seeks EUA
A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.
How A Small Chinese Biotech Is Taking On mRNA Vaccine Giants
Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.